AbbVie entered an exclusive licensing agreement on 10 July with IGI Therapeutics to develop ISB 2001, the only clinical-stage CD3/BCMA/CD38 trispecific antibody for relapsed/refractory multiple myeloma (MM). The deal includes USD 700 million upfront and up to USD 1.225 billion in milestones, granting AbbVie rights in Greater China, Europe, Japan and North America.

ISB 2001 demonstrated 75% objective response rate (ORR) in Phase I trials, including 13% complete responses at doses ≥50μg/kg. The BEAT platform-derived candidate aims to improve safety over existing BCMA-targeted therapies by dual antigen engagement. Global competitors include Innovent Biologics' GPRC5D/BCMA/CD3 trispecific IBI3003 and Simcere's SCR-8572, licensed to AbbVie in January 2025.